DR PEREZ: Essentially HERA looked at 0 versus 1 versus 2. And the PHARE trial looked at 6 months versus 12 months. And the conclusion from those 2 trials taken together is that we all made the right decision by recommending 1 year of adjuvant trastuzumab as the way we tested the drug here in the United States in our trials.
DR LOVE: Any thoughts or comments about these data, Adam?
DR BRUFSKY: It’s interesting. I think that clearly 1 year is the right amount right now. Nothing that we’ve seen so far is going to change that. You could quibble with the trial designs or noninferiority, power, et cetera. Nonetheless, I think that there’s nothing that has come out yet that has told us that anything but 1 year is the right thing to do. And I know the 1 year was totally random.
DR CAREY: No, no, no. They were incredibly clever.
DR PEREZ: Just from the randomness of our decision at the time, we thought that too short was too short. More than 1 year would be too long. That was the science right there.
DR BRUFSKY: I know. That’s what I said. But it was right. They were absolutely right.